Nanox Imaging Signs Exclusive Distribution Agreement with Top Med
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Nanox Imaging announced a distribution agreement with Top Med to deploy the Nanox.ARC system and related services in Peru. Under the agreement, Nanox appointed Top Med as its exclusive distributor of the Nanox.ARC system and Nanox platform in Peru, subject to commercial milestones and regulatory requirements. The agreement is structured as a capex model and includes an expected initial deployment of six Nanox.ARC systems, subject to receipt of the required permits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NNOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NNOX
Wall Street analysts forecast NNOX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.670
Low
7.00
Averages
7.00
High
7.00
Current: 1.670
Low
7.00
Averages
7.00
High
7.00
About NNOX
Nano-X Imaging Ltd is an Israel-based company that develops a digital X-ray source enabling a cost reduction of imaging systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X Imaging reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million charge for impairment of long-lived assets following a restructuring at its Korean chip manufacturing facility, indicating significant financial strain during business adjustments.
- Executive Changes: The company announced that CFO Ran Daniel will step down on July 31, 2026, which may undermine investor confidence in the company's future financial management and exacerbate market uncertainty.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, a 24.39% drop, closing at $2.16 per share, reflecting investor concerns regarding the company's financial health and future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and potential damages, further impacting its market performance.
See More
Nano-X Imaging (NNOX) Q4 2025 Earnings Transcript
See More
Pomerantz LLP Investigates Claims for Nano-X Investors
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating significant financial strain during its transition.
- Executive Change Impact: The announcement that CFO Ran Daniel will resign on July 31, 2026, raises concerns among investors regarding the company's future financial management capabilities, potentially undermining market confidence and affecting stock performance.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting a strong negative market reaction to the company's financial condition and outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to class action risks and further exacerbate investor anxiety.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
- Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
- Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
- Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and is expected to greatly enhance public and workplace safety.
- Market Potential: The company is targeting a market of approximately $47 billion in workplace safety and substance testing, with growing demand for efficient and scalable detection solutions, positioning MindBio's technology for widespread application across various industries.
- Scientific Foundation: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of intoxication states and providing a more comprehensive assessment compared to traditional single-substance tests, with high detection accuracy.
- Social Impact: By reducing traffic accidents and workplace incidents caused by intoxication, MindBio's non-invasive detection methods have the potential to improve public health globally and lower the societal costs associated with substance use.
See More
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge related to restructuring at its Korean chip manufacturing facility, indicating significant financial strain during its transition.
- Executive Departure Impact: CFO Ran Daniel's announcement to step down on July 31, 2026, raises concerns among investors regarding the company's future financial management capabilities, potentially undermining market confidence and affecting stock performance.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting a strong negative market reaction to the company's financial condition and outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to a class action lawsuit and further exacerbate investor anxiety.
See More
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X Imaging reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million charge for impairment of long-lived assets following a restructuring at its Korean chip manufacturing facility, indicating significant financial strain during business adjustments.
- Executive Changes: The company announced that CFO Ran Daniel will step down on July 31, 2026, which may undermine investor confidence in the company's future financial management and exacerbate market uncertainty.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, a 24.39% drop, closing at $2.16 per share, reflecting investor concerns regarding the company's financial health and future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and potential damages, further impacting its market performance.
See More
Nano-X Imaging (NNOX) Q4 2025 Earnings Transcript
See More
Pomerantz LLP Investigates Claims for Nano-X Investors
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating significant financial strain during its transition.
- Executive Change Impact: The announcement that CFO Ran Daniel will resign on July 31, 2026, raises concerns among investors regarding the company's future financial management capabilities, potentially undermining market confidence and affecting stock performance.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting a strong negative market reaction to the company's financial condition and outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to class action risks and further exacerbate investor anxiety.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
- Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
- Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
- Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and is expected to greatly enhance public and workplace safety.
- Market Potential: The company is targeting a market of approximately $47 billion in workplace safety and substance testing, with growing demand for efficient and scalable detection solutions, positioning MindBio's technology for widespread application across various industries.
- Scientific Foundation: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of intoxication states and providing a more comprehensive assessment compared to traditional single-substance tests, with high detection accuracy.
- Social Impact: By reducing traffic accidents and workplace incidents caused by intoxication, MindBio's non-invasive detection methods have the potential to improve public health globally and lower the societal costs associated with substance use.
See More
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge related to restructuring at its Korean chip manufacturing facility, indicating significant financial strain during its transition.
- Executive Departure Impact: CFO Ran Daniel's announcement to step down on July 31, 2026, raises concerns among investors regarding the company's future financial management capabilities, potentially undermining market confidence and affecting stock performance.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting a strong negative market reaction to the company's financial condition and outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to a class action lawsuit and further exacerbate investor anxiety.
See More
